Newsfeeds - Spark Newswire

1 minute read

Nektar Therapeutics Q4 EPS $(0.79) Beats $(0.81) Estimate, Sales $25.01M Miss $25.33M Estimate

February 28, 5:58 PM

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.81) by 2.47 percent. This is a 21.54 percent decrease over losses of $(0.65) per share

NKTR

10 minute read

Earnings Scheduled For February 28, 2022

By Benzinga Insights

February 28, 5:17 AM

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.

AAON

1 minute read

Earnings

Earnings Outlook For Nektar Therapeutics

By Benzinga Insights

February 25, 1:14 PM

Nektar Therapeutics (NASDAQ:NKTR) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Nektar Therapeutics will report an earnings per share (EPS) of $-0.81.

NKTR

12 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

February 4, 1:54 PM

On Friday, 209 companies set new 52-week lows.

ACHL

3 minute read

FDA
News

Nektar Therapeutics Announces Phase 1b Data For Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) In Patients With Atopic Dermatitis

By Benzinga Newsdesk

December 15, 10:11 AM

Nektar Therapeutics (NASDAQ:NKTR) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored Phase 1b proof-of-concept study of NKTR-358 (LY3471851*), a

NKTR

6 minute read

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance

By Shanthi Rexaline

November 10, 9:19 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ACIU

1 minute read

Benchmark Upgrades Nektar Therapeutics to Buy, Announces $20 Price Target

By Benzinga Newsdesk

November 8, 8:42 AM

Benchmark analyst Aydin Huseynov upgrades Nektar Therapeutics (NASDAQ:NKTR) from Hold to Buy and announces $20 price target.

NKTR

7 minute read

92 Biggest Movers From Friday

By Lisa Levin

November 8, 4:42 AM

Gainers

AAOI

5 minute read

64 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

November 5, 12:24 PM

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the estimated price range of $4-$6, for raising gross proceeds of $10 million.

AAOI

1 minute read

Oppenheimer Maintains Perform on Nektar Therapeutics, Lowers Price Target to $21

By Benzinga Newsdesk

November 5, 9:48 AM

Oppenheimer maintains Nektar Therapeutics (NASDAQ:NKTR) with a Perform and lowers the price target from $25 to $21.

NKTR